Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
Part II: to demonstrate that the time to flare in Part II is higher with canakinumab than with placebo. Part I: to assess if canakinumab allows tapering of steroids as per protocol in at least 25% of the patients.
Critère d'inclusion
- Active systemic manifestations of Systemic Juvenile Idiopathic Arthritis (SJIA)